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A B S T R A C T
Background
Restricting sodium intake in elevated blood pressure over short periods of time reduces blood pressure. Long term effects (on mortality,
morbidity or blood pressure) of advice to reduce salt in patients with elevated or normal blood pressure are unclear.
Objectives
To assess in adults the long term effects (mortality, cardiovascular events, blood pressure, quality of life, weight, urinary sodium excretion,
other nutrients and use of anti-hypertensive medications) of advice to restrict dietary sodium using all relevant randomised controlled
trials.
Search strategy
The Cochrane Library, MEDLINE, EMBASE, bibliographies of included studies and related systematic reviews were searched for
unconfounded randomised trials in healthy adults aiming to reduce sodium intake over at least 6 months. Attempts were made to trace
unpublished or missed studies and authors of all included trials were contacted. There were no language restrictions.
Selection criteria
Inclusion decisions were independently duplicated and based on the following criteria: 1) randomisation was adequate; 2) there was
a usual or control diet group; 3) the intervention aimed to reduce sodium intake; 4) the intervention was not multifactorial; 5) the
participants were not children, acutely ill, pregnant or institutionalised; 6) follow-up was at least 26 weeks; 7) data on any of the
outcomes of interest were available.
Data collection and analysis
Decisions on validity and data extraction were made independently by two reviewers, disagreements were resolved by discussion or if
necessary by a third reviewer. Random effects meta-analysis, sub-grouping, sensitivity analysis and meta-regression were performed.
Main results
Three trials in normotensives (n=2326), five in untreated hypertensives (n=387) and three in treated hypertensives (n=801) were
included, with follow up from six months to seven years. The large, high quality (and therefore most informative) studies used intensive
behavioural interventions.
Deaths and cardiovascular events were inconsistently defined and reported; only 17 deaths equally distributed between intervention
and control groups occurred. Systolic and diastolic blood pressures were reduced at 13 to 60 months in those given low sodium advice
as compared with controls (systolic by 1.1 mmHg, 95% CI 1.8 to 0.4, diastolic by 0.6 mm hg, 95% CI 1.5 to -0.3), as was urinary 24
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hour sodium excretion (by 35.5 mmol/ 24 hours, 95% CI 47.2 to 23.9). Degree of reduction in sodium intake and change in blood
pressure were not related. People on anti-hypertensive medications were able to stop their medication more often on a reduced sodium
diet as compared with controls, while maintaining similar blood pressure control.
Reviewer’s conclusions
Intensive interventions, unsuited to primary care or population prevention programmes, provide only minimal reductions in blood
pressure during long-term trials. Further evaluations to assess effects on morbidity and mortality outcomes are needed for populations
as a whole and for patients with elevated blood pressure.
Evidence from a large and small trial showed that a low sodium diet helps in maintenance of lower blood pressure following withdrawal
of antihypertensives. If this is confirmed, with no increase in cardiovascular events, then targeting of comprehensive dietary and
behavioural programmes in patients with elevated blood pressure requiring drug treatment would be justified.
P L A I N L A N G U A G E S U M M A R Y
Synopsis
This review set out to assess the long term effects of advice to cut down on salt in food on deaths, cardiovascular disease and blood
pressure in adults.
Intensive support and encouragement to reduce salt intake did lead to reduction in salt eaten. It also lowered blood pressure but only by
a small amount (about 1 mmHg for systolic blood pressure, less for diastolic) after more than a year. This reduction was not enough to
expect an important health benefit. It was also very hard to keep to a low salt diet. However, the reduction in blood pressure appeared
larger for people with higher blood pressure.
There was not enough information to assess the effect of these changes in salt intake on health or deaths.
Evidence from a large and small trial showed that advice to reduce salt helps to maintain lower blood pressure following withdrawal of
antihypertensive medication. If this is confirmed, with no increase in cardiovascular events, then comprehensive dietary and behavioural
programmes in patients with elevated blood pressure requiring drug treatment would be justified.
See also the Cochrane review of short-term salt reduction trials: Jurgens 2003.
B A C K G R O U N D
There is evidence from published systematic reviews that restrict-
ing sodium intake in people with elevated blood pressure leads
to reductions in blood pressure of about 4 mm hg systolic and 2
mm hg diastolic (Law 1991; Midgley 1996; Cutler 1997; Graudal
1998; Alam 1999; Jurgens 2003). However, within these reviews
many included trials are short term, neither allowing for complete
adjustment of blood pressure to altered sodium intake or to re-
ducedmotivation for following dietary restrictions over time. Also,
some trials increased sodium intake in one arm and compared this
with a reduced sodium intake in the other arm and so do not es-
timate likely effects of cutting down on sodium in a normal diet.
In addition, some reviews suggest that the level of blood pressure
reduction achieved over a longer period in free-living adults is less
impressive than in the short term (Ebrahim 1996; Ebrahim 1998;
Graudal 1998).
A decrease in blood pressure is only important if it results in a
decrease in cardiovascular events and deaths. The published sys-
tematic reviews on the effect of salt restriction on blood pressure
and other risk factor outcomes have expressed different interpre-
tations with regard to the significance of these changes in relation
to cardiovascular events and deaths. This systematic review and
meta-analysis aimed to draw together information on the effect of
long-term dietary salt reduction on health outcomes.
O B J E C T I V E S
This systematic review aimed to study the effects of restricting
2Reduced dietary salt for prevention of cardiovascular disease (Unknown)
Copyright © 2003 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
sodium intake over at least six months in free-living adults, com-
pared with a normal or usual sodium intake.
The specific objectives were to assess, in people with normal and
elevated blood pressure, the effect of advice and/or support to
reduce dietary sodium intake, on deaths and cardiovascular events;
number and dose of anti-hypertensive medications used; quality
of life; weight; systolic and diastolic blood pressure; and urinary
sodium excretion and other nutrient intakes in free-living adults
at least six months after the initial intervention was commenced.
The effects of potential modifiers of salt restriction (i.e. initial level
of blood pressure, categorization into normal or elevated blood
pressure, degree of sodium reduction, gender, race and age) were
also investigated.
R E S U L T S
Mortality and cardiovascular events.
These outcomes were inconsistently reported in trials (see Data
- total deaths and cardiovascular events (including cardiovascular
deaths)). No differences in periods of hospitalisation were seen be-
tween intervention groups in theHPT study (no further data were
provided). Morgan 1978 reported that three control participants
were treated for cardiac failure, as were two on low sodium diets,
with four cardiovascular deaths in the low sodium group and two
in the control group. TONE recorded cardiovascular events (in-
cluding stroke, transient ischaemic attack, myocardial infarction,
angina, congestive heart failure, arrhythmia and ’other’ events) of
participants. Cardiovascular events occurred in 46 control partic-
ipants and 36 of those on low sodium diets. Pooling the two stud-
ies suggests no significant difference in cardiovascular morbidity
between low sodium and control groups (relative risk 0.82, 95%
CI 0.56 to 1.21).
The trials report few deaths, altogether only 9 deaths in control
groups and 8 in low sodium groups (relative risk 0.90, 95% CI
0.36 to 2.24). The available data are shown in the metaview.
Blood pressure.
Changes in blood pressure and urinary sodium excretion at inter-
mediate and late assessments are given in Data - BP & urinary
sodium (’mean (sd)’ for control / ’mean (sd)’ for low salt) and
meta-analysis results in Meta-analysis, sugrouping and sensitivity
analysis results. Systolic blood pressure was reduced on a low salt
diet at both intermediate (by 2.5 mm hg, 95% CI 3.8 to 1.2) and
late follow up (by 1.1 mm hg, 95% CI 1.8 to 0.4). Diastolic blood
pressure was also reduced at intermediate follow up (by 1.2 mm
hg, 95% CI 1.8 to 0.7), less so later (by 0.6 mm hg, 1.5 to -0.3).
The few participants with very late follow up (seven years) had
non-significant reductions in systolic (by 3.8 mm hg, 95% CI 7.9
to -0.3) and diastolic (by 2.2 mm hg, 95% CI 4.8 to -0.4) blood
pressure. It should be noted that this late follow up of the TOHP
phase I study was technically after the end of the trial. TOHP
phase I ran for 18 months with a consistent intervention to help
the low sodium group stick to a low sodiumdiet. The 7-year results
are described as ’posttrial’ results, and as 7 years follow up, and
the trialists implied that they were assessing the long term effect of
their 18 month intervention. We (as reviewers) felt that if the trial
just stopped intervening, without altering the diets of either the
intervention or control groups then we could include data from
the later follow up (in many studies the intervention only happens
once or twice at the beginning, but the effect is measured months
later). The paper states that ’after 18-months, there was no further
contact with the trial participants to enhance the intervention
effect’. We could not contact the reviewers to confirm that there
were no suggested alterations to the diets of the participants after
the eighteenmonth intervention, so the data are included here but
with this note of caution.
Statistical heterogeneity was present for systolic blood pressure at
intermediate follow up and diastolic blood pressure at late follow
up, but was resolved when sensitivity analyses removed trials with
inadequate or unclear allocation concealment, or with imputed
standard deviations, or when trials were sub-grouped into nor-
motensive or hypertensive at baseline.
Sensitivity analysis, excluding trials with inadequate allocation
concealment, resulted in all trials on untreated hypertensives being
removed. As these trials were small, the effect on pooled estimates
of blood pressure change was minor. Adding in data for the weight
reduction arms of factorial trials strongly reduced the effect of low
sodium advice on blood pressure, and slightly reduced the effect
on sodium excretion (Meta-analysis, sugrouping and sensitivity
analysis results).
Meta-regression of blood pressure change up to 12 months using
all trials with relevant data (or trials with adequate allocation con-
cealment, effectively trials on normotensives) showed no relation-
ship with change in urinary sodium excretion, baseline systolic
blood pressure or age (Meta-regression results, effects on SBP at 6
to 12 months). However, the meta-analyses subgrouping by ’nor-
motensive’ or ’hypertensive’ participants at baseline did suggest a
consistently greater effects of salt restriction on blood pressure in
hypertensives. Insufficient data were available of effects on specific
races or genders to enable statistical exploration of these factors.
Quality of Life.
Information on quality of life was patchy, with no common out-
comemeasures. HPT asked participants whether they were having
problems with their diets. 69% of those in the low sodium group
reported problems at some time during the 3 years of the trial, and
problems were reported at 42% of clinic visits. Problems related
to the diet being inconvenient, conflicting with schedules, lack of
time for planning, and difficulty in adherence while eating out.
TOHP phase I reported psychological well-being scores. These
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improved significantly in participants in the low sodium groups
at 18 months compared with the non-intervention control group
(p<0.01). It was stated that the improvement was generally con-
sistent across race and sex subgroups but no further information
was provided.
Thaler (Thaler men 1982; Thaler women 1982) reported that
stopping adding salt at table was not difficult for participants, but
many found cutting down on salt in cooking harder. The majority
found their low salt bread (salt cut from 2.1% to 1.0% dry weight)
and salt-free butter acceptable. Only 13% of participants reported
their salt restricted diet as unpleasant or worse.
TONE found that the most common non-cardiovascular event
recorded was headache: the low sodium group had a significant
reduction in headaches as compared to the control group.
Thaler (Thaler men 1982; Thaler women 1982) asked about pres-
ence or absence of muscle cramps in control and low sodium par-
ticipants. At eight months 13% of control subjects reported get-
ting cramps a lot or sometimes (as opposed to occasionally or
never) whilst this outcome was reported in 30% of the low sodium
group.
Overall drop out rates were very similar (relative risk 1.04, 95%
CI 0.86 to 1.25) in low sodium compared with control groups.
Weight.
The suggestion from food diaries in HPT was that men on a low
sodium diet take in roughly 240 kcal less per day than their control
counterparts. Women on low sodium diets take in 120 fewer kcal
per day. This did not result in a large difference in weight; at 3
years those in the control group had gained about 1 kg on average
more than those in the low sodium group.
TOHP phase I observed significantly greater weight loss in the low
sodium group compared with control at six (1.2 kg) and twelve
(0.8 kg) months, but the difference at 18 months (0.4 kg) was
no longer significant. Similarly, in TOHP phase II those on a
low sodium diet lost more weight initially (1.2 kg difference at
6 months, p<0.001), but the difference had disappeared by 36
months.
Arroll 1995 found a weight loss of 1.4 kg in the low sodium group
relative to the controls at six months. However, Morgan 1987,
Thaler (Thaler men 1982; Thaler women 1982), and Silman
1983, found no change in weight in either control or low sodium
groups.
In TONE eight participants not assigned to a weight loss inter-
vention experienced excessive weight loss, but it is not clear how
many of these were in the control or low sodium groups.
Overall, in the larger studies, where one ismore likely to see any real
effect, there appeared to be initial weight reductions accompanying
the low sodium diet, but the effect was lost over several years.
Urinary sodium excretion.
Meta-analysis demonstrated a reduction in urinary 24 hour
sodium excretion at intermediate (48.9 mmol/ 24 hours, 95% CI
65.4 to 32.5), and late follow up (35.5 mmol/ 24 hours, 95% CI
47.2 to 23.9) in those advised to follow a low sodium diet com-
pared with control. Significant heterogeneity was seen in results at
intermediate and late assessment, and was not resolved by sensitiv-
ity analysis leaving out trials with unclear or inadequate allocation
concealment. The one trial to assess very late outcomes (TOHP
phase I, in normotensives) found that at seven years sodium ex-
cretion in a small subset of their original sample was similar in
intervention and control groups.
Other nutrients.
The relationship between low sodium dietary advice and other
dietary components has not been fully explored in these studies.
Potassium is the most reported component, usually measured as
urinary excretion alongside sodium. Other nutrients were mea-
sured as dietary intakes using food record and recall systems.
Minerals
Potassium. In HPT potassium excretion was consistently greater
in low sodium than control groups (about 6 mmol/24 hours at
3 years) but whether this difference was statistically significant
is not clear. In TONE potassium intake was also greater in the
low sodium group than in control (by 160 mg/24 hours, 95% CI
25 to 295). The rest of the trials found no significant differences
in reported intakes or excretion of potassium including: TOHP
phase I, TOHP phase II, Thaler men 1982, Thaler women 1982,
Morgan 1978, Morgan 1987 and Silman 1983.
Magnesium. TONE found a higher intake of magnesium in low
salt as compared with control groups (by 24 mg/24 hour, 95% CI
8 to 39), whereas TOHP phase I reported no significant difference
between groups.
Calcium. TONE found a significant fall in calcium intake in the
low salt as compared with the control group (of 71 mg/24 hours,
95% CI 119 to 23). HPT found a reduction in salt from dairy
foods (suggested in all groups, but only significant in normal
weight men), while TOHP phase I reported no significant net
differences in reported intake of calcium.
Iron. TOHP phase I reported lower intakes of iron (3.6 mg/day
at 18 months) in the low sodium group. The differences in iron
were due to differences in men (women were similar between low
sodium and control groups) and the reported iron intakes (15 mg/
day at 18 months in men) in the low sodium group were still well
over the RDA (10 mg/day for men). TONE also found lower iron
intakes in the low sodium group (lower by 2.8 mg/24 hours, 95%
CI 3.8 to 1.8).
Phosphorus and zincwere not significantly different in low sodium
and control groups in TONE.
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Vitamins.
TOHP phase I reported no significant net differences in reported
intakes of vitamin A, vitamin C, thiamine, riboflavin or niacin.
TONE found lower intakes of thiamine (0.12 mg/24 hours, 95%
CI 0.22 to 0.02) and riboflavin (0.2 mg/24 hours, 95% CI 0.3
to 0.1) in low sodium groups, but no significant differences in
vitamins A, Bs, C, D, E, folate or niacin (excluding supplements).
Macronutrients.
Energy. TOHP phase I reported significantly lower daily intakes
of total energy (207 kcal) in the low sodium group, as did TONE
(by 119 kcal/24 hours, 95% CI 197 to 41).
Fats. Lower intakes of total fat (by 5.8 g/24 hours, 95% CI 10.1
to 1.5), saturated fat (by 2.4 g/24 hours, 95% CI 4.0 to 0.8) and
monounsaturated fat (by 2.2 g/24 hours, 95% CI 4.0 to 0.4) were
seen in the low sodium group of TONE.No significant differences
were seen in polyunsaturated fat intake. TOHP phase I reported
significantly lower daily intakes of total fat (11.4 g) in the low
sodium group, but no significant net differences in saturated fat.
Alcohol. TOHP phase II reported that there were no differences
between the low sodium and usual care groups in alcohol intake,
while Arroll 1995 reported an increased intake of alcohol in the
control group (2.4 g/day), though it was not clear whether this
was statistically significant. TOHP phase I reported no significant
net differences in reported intake of alcohol.
Protein and carbohydrates were not significantly different in the
low sodium and control groups in TONE.
Overall, there is a trend towards increases in potassium and mag-
nesium, and a fall in calcium, iron, some B vitamins, total energy,
total and saturated fats in low sodium groups.
Anti-hypertensive medications used.
Two trials in patients with elevated blood pressure considered
the ability of low salt diets to maintain blood pressure con-
trol after stopping anti-hypertensive medication. In the smaller
trial (Morgan 1987) anti-hypertensive therapy was stopped two
months after randomisation to usual or low sodium diet, but
restarted if diastolic blood pressure rose. After six months, four of
ten men on low sodium diet were taking anti-hypertensive med-
ication, compared to nine of ten on usual diet (relative risk 0.44,
95% CI 0.20 to 0.98).
In the larger study (TONE, 975 participants, including those on
weight reduction interventions) withdrawal of medication was at-
tempted 3 months after randomisation to low sodium diet (with
behavioural therapy) or usual care. The primary combined end-
point (a combination of high blood pressure at any visit, restart-
ing of anti-hypertensive medication or any clinical cardiovascular
event) was less common in the low sodium group, relative risk
0.83 (95% CI 0.75 to 0.92), ARR 14%, NNT 7.
D I S C U S S I O N
Eleven long term randomised controlled trials of dietary salt reduc-
tion (including 3514 participants) provided few data on mortality
(17 deaths in total), cardiovascular events or quality of life, but
did demonstrate a significant decrease in systolic blood pressure
(1.1 mm hg, 95% CI 1.8 to 0.4) and urinary sodium excretion
(35.5 mmol/24 hours, 95%CI 47.2 to 23.9) at 13 to 60 months
after initial advice. The decrease in diastolic blood pressure was
smaller (0.6 mm hg, 95% CI 1.5 to -0.3). The data suggest that a
low salt diet may help people on anti-hypertensives to stop their
medication without losing blood pressure control. The data from
TONE suggest that for every 7 patients assigned a goal of achiev-
ing a sodium intake of less than 80 mmol/day, one would remain
off antihypertensive medication with a BP less than 150/90 mm
hg and with no adverse cardiovascular events.
Effects of low salt dietary advice on mortality and cardiovascular
morbidity
Health promotion interventions involve several stages before any
health outcome is seen. First, the advice must result in changed
behaviour (cutting down on salt in foods) and secondly that be-
haviour must result in an improved health outcome (reduced car-
diovascular illness, increased life expectancy). A major weakness
of this review is that we were not able to assess the overall effect
of advice to reduce dietary sodium on mortality or morbidity (as
not enough events have been accumulated to see any definitive
answer). Instead we have tried to follow the process by assessing
several intermediate outcomes including urinary sodium excretion
and blood pressure; however there may be effects on other risk
factors.
It is not clear what effects a low sodium diet has on cardio-
vascular events and mortality. It has been suggested that lower-
ing sodium intake may have adverse effects on the vascular en-
dothelium through stimulation of the renin-angiotensin system
(Alderman 1997), and adverse effects on serum total and LDL
cholesterol levels (Graudal 1998) have been suggested. In cohort
studies, lower salt intake in hypertensives has been associated with
higher levels of cardiovascular disease (Alderman 1995) and in
general populations (Alderman 1998; Tunstall-Pedoe 1997) with
greater all-cause mortality. However, among obese people lower
salt intake may be associated with reduced risk of cardiovascular
events (He 1999; Tuomilehto 2001). These apparently contradic-
tory findings emphasizes the fact that we do not know whether
long-term salt restriction is beneficial or harmful.
Effects of low salt dietary advice on sodium excretion
The review suggests that sodium reduction of about a quarter of
usual sodium intake in US and UK populations (MAFF 1999)
can be achieved long term. This may be exaggerated. For example,
HPT found that 48% of participants ate differently on the day of
their food record, eating less food, and substituting simpler foods.
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Several people in the low sodium group also reported eating less
salt on days salt intake was recorded. Whether food adjustment
also occurred when urine samples were collected (and whether
these were complete) is not known. Male participants in Thaler’s
trial (Thaler men 1982) were believed to have relaxed their salt
restriction between urine samples (O. Simpson, personal commu-
nication, 2001).
Is it realistic to ask people to alter their salt intake long term?
Advice to reduce dietary salt is common in primary care if the
British Hypertension Society’s Guidelines (Ramsay 1999; Ramsay
1999a) are being followed. These guidelines advise that ’reduced
use of salt when preparing food and elimination of excessively
salty foods from the diet’ ’be offered to all hypertensive people
and those with a strong family history of hypertension’. It does
appear that the degree of salt restriction attained attenuates over
time (Meta-analysis, sugrouping and sensitivity analysis results)
and this occurs despite a great deal of ongoing encouragement
and support (comprehensive interactive programmes of dietary
andbehavioural education involving specialized andhighly trained
staff, vast input of skills, time and materials) in all of the four large
high quality trials. The resulting falls of 1.1mmhg systolic and 0.6
mm hg in diastolic blood pressure may be useful at a population
level; however the intensity of intervention applied to individuals
required to achieve this is not realistic for community control of
high blood pressure, which would need to be through changes in
food production and catering practices.
Effects of low salt dietary advice on blood pressure
While both urinary sodium excretion and blood pressure fell, the
salt reductionmay not have caused the fall in blood pressure. Alter-
ations in diet aimed at reducing salt intake may perhaps systemati-
cally affect other dietary components (such as alcohol, potassium,
calcium, fat or energy intake) thatmay themselves alter blood pres-
sure (Cappuccio 1991; Allender 1996; Whelton 1997; Ebrahim
1998; Brand 1999; Griffith 1999). The only available data sug-
gest that potassium is not consistently affected by a low sodium
diet, and that weight may be reduced in the medium term, but
is unlikely to be exerting much effect on blood pressure by three
years. Very little information is available on alcohol (suggesting
no major effect), calcium (TOHP phase I reported no significant
changes in intake of calcium, but HPT reported a reduction in
salt from dairy foods) or fat (suggesting that significant reductions
may be occurring in low sodium groups, reported in only one
large trial). The significant reduction in weight of people given low
sodium dietary advice in the medium, but not the longer term,
may explain why the effect of a low sodium diet on blood pressure
’drops off ’ so much between intermediate and late follow up in
this review. It may also explain why, in this review, no relationship
is seen between the degree of reduction in sodium excretion and
change in blood pressure. However the number of trials is small
and relating a mean change in blood pressure to a mean change
in urinary sodium is statistically weak. In previous meta-analyses
(Characteristics of systematic reviews on salt and blood pressure)
a relationship has been seen in some cases but not in others. Indi-
vidual participant data are required to take this issue further.
We expected that short duration trials would achieve larger falls in
blood pressure that would attenuate over time, in line with atten-
uation of salt restriction. Trials in normotensives in in the Graudal
review (Graudal 1998) (Characteristics of systematic reviews on
salt and blood pressure) had a median length of 8 days, a reduc-
tion of 160 mmol/24 hours in urinary sodium excretion and a
fall of 1.2 mm hg in systolic blood pressure, while in this review
(median trial length 36 months, 34 mmol/24 hours difference in
sodium excretion) systolic blood pressure fell by 1.1 mm hg. In
hypertensives our results are less easy to interpret due to the low
quality of included studies, but there is no clear suggestion that
blood pressure effects diminish with longer duration trials or with
smaller reductions in sodium excretion. This suggests that home-
ostatic mechanisms (Navar 1997) do not operate over the longer
term to re-set usual blood pressure levels as might be expected. It
has been suggested that ’usual’ blood pressure may be set in utero
or early childhood (Barker 1998) so it is possible that dietary salt
intake in early childhood has a greater role in determining adult
blood pressure than salt intake in adulthood; however the evidence
is mixed (Lucas 1988; Hofman 1983; Singhal 2001), and open
to varying interpretations (He 2001). A systematic review in this
area would be helpful.
Part of the blood pressure lowering effect at longer follow up may
be due to lower sodium diets preventing blood pressure rise with
age. The Intersalt observational study (Elliott 1996) suggested that
a population excreting 100 mmol/day less sodium would experi-
ence a 10 and 6 mm hg lower rise in systolic and diastolic blood
pressure over 30 years. This review suggests that voluntary reduc-
tion of only 35 mmol Na/ 24 hours is realistic for periods of over
one year. This would prevent 3-4 mm hg systolic (2 mm hg dias-
tolic) blood pressure rise over thirty years. However, the sodium
reduction achieved may decline over time so this additional pro-
tective effect of low salt advice may be limited.
The sodium reduction arms of the DASH (Sacks 2001) study are
not included in this review as their intervention periods were only
30 days; however the strength of the study was in providing all
food for participants and so tightly regulating sodium (as well as
potassium and calorie) intake. Participants in the ’control inter-
mediate sodium’ arm reduced their sodium excretion by 35mmol/
day compared with the ’control normal sodium’ arm, reducing
systolic (2.1 mm hg, 95% CI 3.4 to 0.8 mm hg) and diastolic (1.1
mm hg, 95% CI 1.9 to 0.2 mm hg) blood pressure by amounts
similar to those seen in 13-60month followup in this review.With
greater reductions in sodium, systolic blood pressure decreased by
a greater amount ( 6.7 mm hg. 95% CI 5.4 to 8.0).
Effects of low salt dietary advice on other outcomes
There is evidence that a low sodium diet improves the chance
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of maintaining controlled blood pressure following withdrawal of
antihypertensives.
There are several reasons for assessing levels of other nutrients in
a low sodium diet. Altering any one component of a complex
diet will in turn alter the intake of many other micro and macro-
nutrients. It is important to ensure that a low sodium diet is nutri-
tionally adequate. It is also necessary to be aware that changes in
many nutrients have their own long term effects on blood pressure
and other aspects of cardiovascular health. The available data are
scant but suggest increases in potassium and magnesium intake,
and reductions in energy and total fat intakes, all of which might
be expected to help reduce blood pressure in their own right as well
as protecting against cardiovascular disease in other ways. This is
good news for health, but raises further questions about the extent
of the effect of salt reduction itself on blood pressure. It may be
that the small changes in blood pressure seen in these long term
trials are due to increases in potassium and decreases in fat intake.
On the other hand, the reductions in calcium and iron seen in
some trials might endanger dietary adequacy for a few people, in-
creasing the risk of osteoporosis and anaemia. It may be that the
effect on blood pressure, and more generally on health, of a low
sodium diet depends on the types of messages used, the specific
dietary measures taken. These may differ considerably from trial
to trial, or even from participant to participant.
We have included only a small number of the many randomised
controlled trials on the effect of salt manipulation, and none of the
intra- or inter-population surveys, cohorts or animal trials that are
commonly referred to when the effect of salt reduction on health is
discussed. Most of the randomised controlled trials that have been
performed have been of short duration and do not assess whether
dietary advice has any long term effect on health outcomes or
blood pressure. Despite an extensive search, only eleven trials ful-
filled our inclusion criteria (determined by our question). Where
randomised controlled trials in humans are available to answer a
question on health, it would be inappropriate to include animal
studies, surveys or cohort studies, which have contradictory results
and interpretations (Taubes 1998).
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